



ASX Announcement

14 April 2025

Change of registry address notification

Sydney, Australia; Monday 14 April 2025: Cambium Bio Limited (ASX:CMB) (**Cambium Bio, or Company**) advises that in accordance with ASX Listing Rule 3.15.1 and with effect from 14 April 2025, the Sydney office of our registry, MUFG Corporate Markets (AU) Limited, is moving to:

MUFG Corporate Markets (AU) Limited
Liberty Place
Level 41
161 Castlereagh St
Sydney NSW 2000

Telephone numbers and postal address remain unchanged.

- ENDS -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Helen Leung
Corporate Secretary
info@cambium.bio
1 300 995 098